ROME, July 16 (Reuters) - Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal involving Italian state ...
Catalyst Pharmaceuticals (NASDAQ:CPRX) stockholders approved the company’s proposed merger with Angelini Pharma S.p.A. at a ...
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and ...
The entry into the capital accompanies the acquisition of Catalyst Pharmaceuticals, a €3,5 billion operation that strengthens ...
Funding will support nationwide expansion of Handspring's clinician-led, evidence-based care model and technology platform for pediatric mental ...
Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG1051, a pre-clinical investigational novel compound with broad potential to treat brain ...
- The collaboration agreement combines Angelini Pharma’s expertise in neurological diseases with JCR Pharmaceuticals’ scientific and technological excellence to deliver biotherapeutics across the ...
ROME, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Angelini Pharma, part of the privately owned Angelini Industries, and Sovargen, a South-Korean biotechnology company, announced today that they signed an ...
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results